Form 8-K - Current report:
SEC Accession No. 0001437749-25-018972
Filing Date
2025-05-30
Accepted
2025-05-30 16:09:02
Documents
16
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20250513_8k.htm   iXBRL 8-K 33294
2 EXHIBIT 1.1 ex_820842.htm EX-1.1 260324
3 EXHIBIT 5.1 ex_817059.htm EX-5.1 8706
8 lslogo.jpg GRAPHIC 12187
  Complete submission text file 0001437749-25-018972.txt   528659

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rvph-20250530.xsd EX-101.SCH 4042
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20250530_def.xml EX-101.DEF 13797
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20250530_lab.xml EX-101.LAB 18159
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20250530_pre.xml EX-101.PRE 13829
18 EXTRACTED XBRL INSTANCE DOCUMENT rvph20250513_8k_htm.xml XML 4854
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 251010944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)